Therapeutic Market
Therapeutic
In this section you will find information products, including market insight and company profiles, covering major therapeutic sectors, including CNS, Obesity, Oncology, Vaccines and Women's Health.
Stay up-to-date with new products added to this category »
| Title | Publication Date | Price |
|---|---|---|
| Immunomodulators Market to 2017 Immunosuppressant Antibodies to Replace Antimetabolites as the Highest Value Sector by 2017 |
February 2012 | £2215 |
| Multi-therapy Drugs Opportunities for Generics & Biosimilars |
January 2012 | £995 |
| Indian Diagnostic & Therapeutic Antibodies Market Report & Forecast 2011-2016 |
January 2012 | £630 |
| Men's Health Therapeutics Market to 2017 Availability of Generic Sildenafil from 2012 to Restrain Market Growth |
January 2012 | £2215 |
| Solid Organ Transplant Immunosuppressant Market to 2018 Limited Availability of Donors Drives Improvements in Organ Procurement and Preservation Methods |
January 2012 | £2215 |
| Dermatology Therapeutics Market to 2017 Alopecia Market Is Forecast to Decline Due to Patent Expiry of Finasteride in 2013 and Weak Pipeline |
January 2012 | £2215 |
| Musculoskeletal Disorders Therapeutics Market to 2017 Osteoarthritis Market to Decline with Patent Expiry of Celebrex in 2014 |
January 2012 | £2215 |
| Hepatitis Market to 2017 Strong Hepatitis-C Pipeline, Large Number of Strategic Consolidations and Cost Effective Treatments will Drive the Market |
January 2012 | £2215 |
| Top 150 Antibiotic Manufacturers (Global) | January 2012 | £950 |
| ENT Disorders Market to 2017 Cephalosporins, Quinolones and Macrolides to Replace Older Therapies Due to Anti-Bacterial Resistance |
January 2012 | £2215 |
| Personalized Medicine (2 parts) Technologies, Markets and Companies |
January 2012 | £3240 |
| Evolution in the Pain Therapy Drugs Market Nociceptive and Neuropathic Drug Development |
January 2012 | £1295 |
| Graft Versus Host Disease (GVHD) Therapeutics Pipeline Assessment and Market Forecasts to 2018 |
January 2012 | £2525 |
| China Osteoporosis Market Analysis and Forecast 2007 - 2015 |
January 2012 | £950 |
| Cell therapy (2 parts) Technologies, Markets and Companies |
January 2012 | £3560 |
| Eczema Therapeutics Pipeline Assessment and Market Forecasts to 2018 |
January 2012 | £2215 |
| Overactive Bladder (OAB) Therapeutics Pipeline Assessment and Market Forecasts to 2019 |
January 2012 | £2525 |
| Antiviral Therapeutics Technologies, Markets and Companies |
January 2012 | £2265 |
| Pain Therapeutics Technologies, Markets and Companies |
January 2012 | £2590 |
| Women's Health Therapeutics Market to 2017 High Unmet Need will Drive Uptake of Novel Drugs Such as Prolia and Odanocantib in the Menopause and Osteoporosis Market |
January 2012 | £2215 |
| Gallbladder Cancer Therapeutics Pipeline Assessment and Market Forecasts to 2018 |
December 2011 | £2215 |
| Oncology Devices Market to 2017 Improved Efficiency, Shorter Treatment Times and Cost-Effectiveness to Boost the Brachytherapy Devices Segment |
December 2011 | £2215 |
| Oncology Therapeutics Market to 2017 High Unmet Need in the Management and Treatment of Metastatic Cancers to Drive Drug Development |
December 2011 | £2215 |
| Crohn's Disease (CD) Therapeutics Pipeline Assessment and Market Forecasts to 2018 |
December 2011 | £2215 |
| Osteoporosis Therapeutics Pipeline Assessment and Market Forecasts to 2018 |
December 2011 | £2215 |
| Celiac Disease Pipeline Assessment and Market Forecasts to 2019 |
December 2011 | £2215 |
| Sickle Cell Anemia Therapeutics Pipeline Assessment and Market Forecasts to 2018 |
December 2011 | £2215 |
| Bronchitis Therapeutics Pipeline Assessment and Market Forecasts to 2018 |
December 2011 | £2215 |
| Huntington's Disease (HD) Therapeutics Pipeline Assessment and Market Forecasts to 2018 |
December 2011 | £2215 |
| Fibromyalgia Therapeutics Pipeline Assessment and Market Forecasts to 2018 |
December 2011 | £2215 |
